专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US4500450A Polypeptide having an action on the immunological system, process for its isolation and purification, its use, agents containing this compound, and its cleavage products, their use and agents containing these products 失效
标题翻译：对免疫系统具有作用的多肽，其分离和纯化方法，其用途，含该化合物的试剂及其裂解产物，其使用和含有这些产物的试剂
公开(公告)号：US4500450A
公开(公告)日：1985-02-19
申请号：US522204
申请日：1983-08-11
申请人： Gerhard Seipke , Dominique Tripier , Gerd Johnscher
发明人： Gerhard Seipke , Dominique Tripier , Gerd Johnscher
IPC分类号： A61K38/00 , A61K38/22 , A61P37/00 , C07K1/113 , C07K1/20 , C07K14/435 , C07K14/47 , C07K14/575 , G01N33/50
CPC分类号： C07K14/575 , C07K14/47 , A61K38/00 , Y10S530/837 , Y10S530/838 , Y10S530/854
摘要： The invention relates to a polypeptide which can be isolated from thymus glands and has an action on the immunological system, and which has a molecular weight of 3,480, a UV absorption with a maximum at 205 to 210 nm and an isoelectric point of 3.95+0.15 and a specific aminoacid composition, the N-terminal, if appropriate, carrying an acyl group or an acylglycyl group, processes for its isolation and purification, its use, agents containing this polypeptide, and its cleavage products, their use and agents containing them.
摘要翻译：本发明涉及可从胸腺中分离并对免疫系统具有作用的多肽，其分子量为3480，在205至210nm处最大的UV吸收和3.95±0.15的等电点和特定的氨基酸组合物，N-末端，如果合适，携带酰基或酰基甘氨酰基，其分离和纯化过程，其用途，含有这种多肽的试剂，及其裂解产物，其使用和含有它们的试剂。

2. 发明授权

US4526717A Polypeptide having an action on the immunological system, processes for its isolation and purification, its use, agents containing this compound, and its cleavage products, their use and agents containing these products 失效
标题翻译：对免疫系统具有作用的多肽，其分离和纯化方法，其用途，含该化合物的试剂及其裂解产物，其使用和含有这些产物的试剂
公开(公告)号：US4526717A
公开(公告)日：1985-07-02
申请号：US627647
申请日：1984-07-03
申请人： Gerhard Seipke , Dominique Tripier , Gerd Johnscher
发明人： Gerhard Seipke , Dominique Tripier , Gerd Johnscher
IPC分类号： A61K38/00 , A61K38/22 , A61P37/00 , C07K1/113 , C07K1/20 , C07K14/435 , C07K14/47 , C07K14/575 , C07C103/52 , C07G7/00
CPC分类号： C07K14/575 , C07K14/47 , A61K38/00 , Y10S530/837 , Y10S530/838 , Y10S530/854
摘要： The invention relates to a polypeptide which can be isolated from thymus glands and has an action on the immunological system, and which has a molecular weight of 3,480, a UV absorption with a maximum at 205 to 210 nm and an isoelectric point of 3.95+0.15 and a specific aminoacid composition, the N-terminal, if appropriate, carrying an acyl group or an acylglycyl group, processes for its isolation and purification, its use, agents containing this polypeptide, and its cleavage products, their use and agents containing them.
摘要翻译：本发明涉及可从胸腺中分离并对免疫系统具有作用的多肽，其分子量为3480，在205至210nm处最大的UV吸收和3.95±0.15的等电点和特定的氨基酸组合物，N-末端，如果合适，携带酰基或酰基甘氨酰基，其分离和纯化过程，其用途，含有这种多肽的试剂，及其裂解产物，其使用和含有它们的试剂。

3. 发明授权

US06686177B1 Insulin analogs with enhanced zinc binding 有权
标题翻译：胰岛素类似物具有增强的锌结合
公开(公告)号：US06686177B1
公开(公告)日：2004-02-03
申请号：US09701968
申请日：2001-05-14
申请人： Johann Ertl , Paul Habermann , Karl Geisen , Gerhard Seipke , Axel Wollmer
发明人： Johann Ertl , Paul Habermann , Karl Geisen , Gerhard Seipke , Axel Wollmer
IPC分类号： A61K3828
CPC分类号： C07K14/62 , A61K38/00 , Y10S514/866
摘要： The invention relates to insulin analogs exhibiting enhanced zinc binding capacity and to stable zinc complexes thereof having a retarded activity in comparison with human insulin. The invention further relates to a method for the production of said insulin analogs and to their use, particularly in pharmaceutical preparations for therapy of type I and type II diabetes mellitus.
摘要翻译：本发明涉及具有增强的锌结合能力的胰岛素类似物和与人胰岛素相比具有延迟活性的稳定的锌络合物。本发明还涉及生产所述胰岛素类似物的方法及其用途，特别是用于治疗I型和II型糖尿病的药物制剂。

4. 发明授权

US4644057A Process for the cleavage of peptides and proteins at the methionyl bond using cyanogen chloride 失效
标题翻译：使用氯化氰在甲硫氨酰键处裂解肽和蛋白质的方法
公开(公告)号：US4644057A
公开(公告)日：1987-02-17
申请号：US795920
申请日：1985-11-07
申请人： Richard Bicker , Gerhard Seipke
发明人： Richard Bicker , Gerhard Seipke
IPC分类号： C07K1/14 , C07K1/107 , C07K1/12 , C07K17/00 , C12N9/99 , C12N11/02
CPC分类号： C07K1/126 , C07K1/12 , Y10S530/812
摘要： The invention relates to a process for the cleavage of peptides and proteins at the methionyl bond using cyanogen chloride.
摘要翻译：本发明涉及使用氯化氰在甲硫氨酰键处切割肽和蛋白质的方法。

5. 发明授权

US08603970B2 Insulin derivatives having an extremely delayed time-action profile 有权
公开(公告)号：US08603970B2
公开(公告)日：2013-12-10
申请号：US12820727
申请日：2010-06-22
申请人： Paul Habermann , Gerhard Seipke , Roland Kurrle , Gunter Muller , Mark Sommerfeld , Norbert Tennagels , Georg Tschank , Ulrich Werner
发明人： Paul Habermann , Gerhard Seipke , Roland Kurrle , Gunter Muller , Mark Sommerfeld , Norbert Tennagels , Georg Tschank , Ulrich Werner
IPC分类号： A61K38/28 , A61K38/26
摘要： The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the addition and/or substitution of negatively and positively charged amino acid residues and by an amidation of the C-terminal carboxy group of the B chain and histidine in position 8 of the insulin A chain. The invention also relates to the production and use thereof.

6. 发明申请

US20070099821A1 METHOD OF ACTIVATING INSULIN RECEPTOR SUBSTRATE-2 TO STIMULATE INSULIN PRODUCTION 审中-公开
标题翻译：激活胰岛素受体底物-2刺激胰岛素生产的方法
公开(公告)号：US20070099821A1
公开(公告)日：2007-05-03
申请号：US11609530
申请日：2006-12-12
申请人： Gerhard Seipke , Irini Rakatzi , Olaf Dransfeld , Jurgen Eekel
发明人： Gerhard Seipke , Irini Rakatzi , Olaf Dransfeld , Jurgen Eekel
IPC分类号： A61K38/28
CPC分类号： A61K38/28
摘要： The invention relates to new methods and compositions for treating diabetics, pre-diabetics, and patients at risk of becoming diabetic or with impaired glucose tolerance. The invention, in one embodiment, involves activating insulin receptor substrate-2 to protect against loss of beta cell mass, protect against loss of beta cell function, rejuvenate beta cells mass, rejuvenate beta cell function or any combination thereof, thereby stimulate insulin production using an effective amount of LysB3,GluB29 insulin to patients in need of this treatment.
摘要翻译：本发明涉及用于治疗糖尿病患者，糖尿病前期患者和患有糖尿病风险或葡萄糖耐量降低的患者的新方法和组合物。在一个实施方案中，本发明涉及激活胰岛素受体底物-2以防止β细胞团的损失，保护β细胞功能丧失，恢复β细胞的质量，恢复β细胞功能或其任何组合，从而利用有效量的Lys B3，Glu B29胰岛素给需要这种治疗的患者。

7. 发明授权

US06221633B1 Insulin derivatives having a rapid onset of action 失效
标题翻译：具有快速起效的胰岛素衍生物
公开(公告)号：US06221633B1
公开(公告)日：2001-04-24
申请号：US09099307
申请日：1998-06-18
申请人： Johann Ertl , Paul Habermann , Karl Geisen , Gerhard Seipke
发明人： Johann Ertl , Paul Habermann , Karl Geisen , Gerhard Seipke
IPC分类号： C12N1517
CPC分类号： C07K14/62 , A61K38/00 , C07K2319/00 , Y10S514/866
摘要： The present invention relates to insulin derivatives which in comparison to human insulin, have an accelerated onset of action, to a process for their preparation and to their use, in particular in pharmaceutical preparations for the treatment of diabetes mellitus. In particular, the present invention relates to insulin derivatives or physiologically tolerable salts thereof in which asparagine (Asn) in position B3 of the B chain is replaced by a naturally occurring basic amino acid residue and at least one amino acid residue in the positions B27, B28 or B29 of the B chain is replaced by another naturally occurring amino acid residue, it optionally being possible for asparagine (Asn) in position 21 of the A chain to be replaced by Asp, Gly, Ser, Thr or Ala and for phenylalanine (Phe) in position B1 of the B chain and the amino acid residue in position B30 of the B chain to be absent.
摘要翻译：本发明涉及与人胰岛素相比，加速起效的胰岛素衍生物，其制备方法及其用途，特别是用于治疗糖尿病的药物制剂中。特别地，本发明涉及胰岛素衍生物或其生理上可耐受的盐，其中B链B3位的天冬酰胺（Asn）被天然存在的碱性氨基酸残基和B27位置的至少一个氨基酸残基所取代， B链的B28或B29被另一个天然存在的氨基酸残基替代，其任选可能是由A，A，D，Gly，Ser，Thr或Ala代替的A链的第21位的天冬酰胺（Asn）和苯丙氨酸 Phe）在B链的位置B1和B链的位置B30的氨基酸残基不存在。

8. 发明申请

US20060172923A1 Method of activating insulin receptor substrate-2 to stimulate insulin production 审中-公开
标题翻译：激活胰岛素受体底物-2以刺激胰岛素生成的方法
公开(公告)号：US20060172923A1
公开(公告)日：2006-08-03
申请号：US11398869
申请日：2006-04-06
申请人： Gerhard Seipke , Irini Rakatzi , Olaf Dransfeld , Juergen Eckel
发明人： Gerhard Seipke , Irini Rakatzi , Olaf Dransfeld , Juergen Eckel
IPC分类号： A61K38/28
CPC分类号： A61K38/28
摘要： The invention relates to new methods and compositions for treating diabetics, pre-diabetics, and patients at risk of becoming diabetic or with impaired glucose tolerance. The invention, in one embodiment, involves activating insulin receptor substrate-2 to protect against loss of beta cell mass, protect against loss of beta cell function, rejuvenate beta cells mass, rejuvenate beta cell function or any combination thereof, thereby stimulate insulin production using an effective amount of LySB3,GluB29 insulin to patients in need of this treatment.
摘要翻译：本发明涉及用于治疗糖尿病患者，糖尿病前期患者和患有糖尿病风险或葡萄糖耐量降低的患者的新方法和组合物。在一个实施方案中，本发明涉及激活胰岛素受体底物-2以防止β细胞团的损失，保护β细胞功能丧失，恢复β细胞的质量，恢复β细胞功能或其任何组合，从而利用有效量的LysS B3，Glu B29胰岛素给需要这种治疗的患者。

9. 发明授权

US06875589B1 Mini-proinsulin, its preparation and use 失效
标题翻译：迷你胰岛素原，其制备和用途
公开(公告)号：US06875589B1
公开(公告)日：2005-04-05
申请号：US08402394
申请日：1995-03-10
申请人： Michael Dörschug , Paul Habermann , Gerhard Seipke , Eugen Uhlmann
发明人： Michael Dörschug , Paul Habermann , Gerhard Seipke , Eugen Uhlmann
IPC分类号： A61K38/00 , C07K14/62 , C12N1/21 , C12N15/17 , A61K38/28 , C12N1/16
CPC分类号： C07K14/62 , A61K38/00
摘要： A mini-proinsulin, in which the amino acid Arg bridges the A and the B chain instead of the C chain, shows insulin activity and is suitable for the preparation of pharmaceuticals for the treatment of diabetes mellitus. It can furthermore be converted into an insulin derivative simply using trypsin, the B chain of which is lengthened by Arg. This can be converted into insulin using carboxypeptidase B. Advantageously, however, the mini-proinsulin can also be converted to insulin directly in a one-pot process.
摘要翻译：其中氨基酸Arg桥接A和B链而不是C链的微型胰岛素原显示胰岛素活性，并且适用于制备用于治疗糖尿病的药物。胰蛋白酶可以简单地转化为胰岛素衍生物，其中B链被Arg延长。这可以使用羧肽酶B转化成胰岛素。然而，有益的是，微型胰岛素原也可以在一锅法中直接转化为胰岛素。

10. 发明授权

US4601852A Process for the preparation of human or the derivatives thereof from pig insulin or the derivatives thereof 失效
标题翻译：从猪胰岛素或其衍生物制备人或其衍生物的方法
公开(公告)号：US4601852A
公开(公告)日：1986-07-22
申请号：US641357
申请日：1984-08-15
申请人： Rainer Obermeier , Jurgen Ludwig , Gerhard Seipke
发明人： Rainer Obermeier , Jurgen Ludwig , Gerhard Seipke
IPC分类号： C12P21/02 , A61K38/28 , C07K1/12 , C07K14/62 , C07K7/40
CPC分类号： C07K14/62
摘要： What is disclosed is a method for making human insulin or modified human insulin from pig insulin or modified pig insulin by reacting the pig insulin starting material at a pH below its isoelectric point with an excess of a threonine ester in the presence of trypsin or a trypsin-like enzyme.
摘要翻译：公开的是通过在胰蛋白酶或胰蛋白酶存在下，使猪胰岛素起始物质在低于其等电点的pH与过量的苏氨酸酯反应从猪胰岛素或修饰的猪胰岛素制备人胰岛素或修饰的人胰岛素的方法类酶。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式